Autologous bone marrow mononuclear cells to treat severe traumatic brain injury in children
© The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For commercial re-use, please contact reprintsoup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com..
Autologous bone marrow mononuclear cells (BMMNCs) infused after severe traumatic brain injury have shown promise for treating the injury. We evaluated their impact in children, particularly their hypothesized ability to preserve the blood-brain barrier and diminish neuroinflammation, leading to structural CNS preservation with improved outcomes. We performed a randomized, double-blind, placebo-sham-controlled Bayesian dose-escalation clinical trial at two children's hospitals in Houston, TX and Phoenix, AZ, USA (NCT01851083). Patients 5-17 years of age with severe traumatic brain injury (Glasgow Coma Scale score ≤ 8) were randomized to BMMNC or placebo (3:2). Bone marrow harvest, cell isolation and infusion were completed by 48 h post-injury. A Bayesian continuous reassessment method was used with cohorts of size 3 in the BMMNC group to choose the safest between two doses. Primary end points were quantitative brain volumes using MRI and microstructural integrity of the corpus callosum (diffusivity and oedema measurements) at 6 months and 12 months. Long-term functional outcomes and ventilator days, intracranial pressure monitoring days, intensive care unit days and therapeutic intensity measures were compared between groups. Forty-seven patients were randomized, with 37 completing 1-year follow-up (23 BMMNC, 14 placebo). BMMNC treatment was associated with an almost 3-day (23%) reduction in ventilator days, 1-day (16%) reduction in intracranial pressure monitoring days and 3-day (14%) reduction in intensive care unit (ICU) days. White matter volume at 1 year in the BMMNC group was significantly preserved compared to placebo [decrease of 19 891 versus 40 491, respectively; mean difference of -20 600, 95% confidence interval (CI): -35 868 to -5332; P = 0.01], and the number of corpus callosum streamlines was reduced more in placebo than BMMNC, supporting evidence of preserved corpus callosum connectivity in the treated groups (-431 streamlines placebo versus -37 streamlines BMMNC; mean difference of -394, 95% CI: -803 to 15; P = 0.055), but this did not reach statistical significance due to high variability. We conclude that autologous BMMNC infusion in children within 48 h after severe traumatic brain injury is safe and feasible. Our data show that BMMNC infusion led to: (i) shorter intensive care duration and decreased ICU intensity; (ii) white matter structural preservation; and (iii) enhanced corpus callosum connectivity and improved microstructural metrics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:147 |
|---|---|
| Enthalten in: |
Brain : a journal of neurology - 147(2024), 5 vom: 03. Mai, Seite 1914-1925 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cox, Charles S [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.05.2024 Date Revised 05.05.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/brain/awae005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366720457 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366720457 | ||
| 003 | DE-627 | ||
| 005 | 20240505232056.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/brain/awae005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1398.xml |
| 035 | |a (DE-627)NLM366720457 | ||
| 035 | |a (NLM)38181433 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cox, Charles S |c Jr |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Autologous bone marrow mononuclear cells to treat severe traumatic brain injury in children |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.05.2024 | ||
| 500 | |a Date Revised 05.05.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For commercial re-use, please contact reprintsoup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. | ||
| 520 | |a Autologous bone marrow mononuclear cells (BMMNCs) infused after severe traumatic brain injury have shown promise for treating the injury. We evaluated their impact in children, particularly their hypothesized ability to preserve the blood-brain barrier and diminish neuroinflammation, leading to structural CNS preservation with improved outcomes. We performed a randomized, double-blind, placebo-sham-controlled Bayesian dose-escalation clinical trial at two children's hospitals in Houston, TX and Phoenix, AZ, USA (NCT01851083). Patients 5-17 years of age with severe traumatic brain injury (Glasgow Coma Scale score ≤ 8) were randomized to BMMNC or placebo (3:2). Bone marrow harvest, cell isolation and infusion were completed by 48 h post-injury. A Bayesian continuous reassessment method was used with cohorts of size 3 in the BMMNC group to choose the safest between two doses. Primary end points were quantitative brain volumes using MRI and microstructural integrity of the corpus callosum (diffusivity and oedema measurements) at 6 months and 12 months. Long-term functional outcomes and ventilator days, intracranial pressure monitoring days, intensive care unit days and therapeutic intensity measures were compared between groups. Forty-seven patients were randomized, with 37 completing 1-year follow-up (23 BMMNC, 14 placebo). BMMNC treatment was associated with an almost 3-day (23%) reduction in ventilator days, 1-day (16%) reduction in intracranial pressure monitoring days and 3-day (14%) reduction in intensive care unit (ICU) days. White matter volume at 1 year in the BMMNC group was significantly preserved compared to placebo [decrease of 19 891 versus 40 491, respectively; mean difference of -20 600, 95% confidence interval (CI): -35 868 to -5332; P = 0.01], and the number of corpus callosum streamlines was reduced more in placebo than BMMNC, supporting evidence of preserved corpus callosum connectivity in the treated groups (-431 streamlines placebo versus -37 streamlines BMMNC; mean difference of -394, 95% CI: -803 to 15; P = 0.055), but this did not reach statistical significance due to high variability. We conclude that autologous BMMNC infusion in children within 48 h after severe traumatic brain injury is safe and feasible. Our data show that BMMNC infusion led to: (i) shorter intensive care duration and decreased ICU intensity; (ii) white matter structural preservation; and (iii) enhanced corpus callosum connectivity and improved microstructural metrics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a autologous | |
| 650 | 4 | |a bone marrow mononuclear cells | |
| 650 | 4 | |a children | |
| 650 | 4 | |a magnetic resonance imaging | |
| 650 | 4 | |a stem cells | |
| 650 | 4 | |a traumatic brain injury | |
| 700 | 1 | |a Notrica, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Juranek, Jenifer |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Jeffrey H |e verfasserin |4 aut | |
| 700 | 1 | |a Triolo, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Kosmach, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Savitz, Sean I |e verfasserin |4 aut | |
| 700 | 1 | |a Adelson, P David |e verfasserin |4 aut | |
| 700 | 1 | |a Pedroza, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Olson, Scott D |e verfasserin |4 aut | |
| 700 | 1 | |a Scott, Michael C |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Akshita |e verfasserin |4 aut | |
| 700 | 1 | |a Aertker, Benjamin M |e verfasserin |4 aut | |
| 700 | 1 | |a Caplan, Henry W |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, Margaret L |e verfasserin |4 aut | |
| 700 | 1 | |a Gill, Brijesh S |e verfasserin |4 aut | |
| 700 | 1 | |a Hetz, Robert A |e verfasserin |4 aut | |
| 700 | 1 | |a Lavoie, Michael S |e verfasserin |4 aut | |
| 700 | 1 | |a Ewing-Cobbs, Linda |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Brain : a journal of neurology |d 1945 |g 147(2024), 5 vom: 03. Mai, Seite 1914-1925 |w (DE-627)NLM000126292 |x 1460-2156 |7 nnns |
| 773 | 1 | 8 | |g volume:147 |g year:2024 |g number:5 |g day:03 |g month:05 |g pages:1914-1925 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/brain/awae005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 147 |j 2024 |e 5 |b 03 |c 05 |h 1914-1925 | ||